Pharsight

Orserdu patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8399520 STEMLINE THERAP Selective estrogen receptor modulator
Dec, 2024

(7 months from now)

US7612114 STEMLINE THERAP Selective estrogen receptor modulator
Aug, 2026

(2 years from now)

US10385008 STEMLINE THERAP Polymorphic forms of RAD1901-2HCL
Jan, 2038

(13 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10071066 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(10 years from now)

US10420734 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(10 years from now)

US11779552 STEMLINE THERAP Method of treating cancer using selective estrogen receptor modulators
Oct, 2034

(10 years from now)

US11819480 STEMLINE THERAP Methods for treating cancer
Nov, 2036

(12 years from now)

US10745343 STEMLINE THERAP Polymorphic forms of RAD1901-2HCl
Jan, 2038

(13 years from now)

Orserdu is owned by Stemline Therap.

Orserdu contains Elacestrant Dihydrochloride.

Orserdu has a total of 8 drug patents out of which 0 drug patents have expired.

Orserdu was authorised for market use on 27 January, 2023.

Orserdu is available in tablet;oral dosage forms.

Orserdu can be used as treatment of an er-positive breast cancer following at least one line of endocrine therapy, treatment of an er-positive breast cancer.

Drug patent challenges can be filed against Orserdu from 27 January, 2027.

The generics of Orserdu are possible to be released after 05 January, 2038.

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Jan 27, 2028

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Drugs and Companies using ELACESTRANT DIHYDROCHLORIDE ingredient

NCE-1 date: 27 January, 2027

Market Authorisation Date: 27 January, 2023

Treatment: Treatment of an er-positive breast cancer following at least one line of endocrine therapy; Treatment of an er-positive breast cancer

Dosage: TABLET;ORAL

More Information on Dosage

ORSERDU family patents

Family Patents